News and Trends 4 Apr 2023 iNtRON looks to control colorectal cancer through microbiome iNtRON Biotechnology has announced that it has demonstrated the effectiveness of P18-BE3CRC using a cancer organoid model. P18-BE3CRC is a drug candidate from iNtRON Biotechnology’s PHAGERIA platform technology, which is for the development and commercialization of bacteriophage-based drugs (Phageome API) for cancer control. Bacteriophages have been used for R&D on bacterial infectious diseases, but recently […] April 4, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 New research may lead to gene therapies for kidney disease Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially lethal genetic disease—about a half million people in the U.S. alone suffer from the condition. There is currently no cure, but new research could open the door to new gene therapies for treating most cases of this kidney disease. For several decades, researchers have […] April 4, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Apr 2023 Discovery could lead to cancer drugs with fewer side effects Many anticancer drugs have serious side-effects in clinical practice. Kinesin inhibitors block kinesin motor proteins required for cancer cell division, and are promising anticancer drug candidates with minimal side-effects. However, their association with kinesin proteins remains unclear. Researchers from Japan have addressed this by solving the crystal structure of the complex formed by the kinesin […] April 4, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Sponsored by MC Services 3 Apr 2023 BIO-Europe Spring 2023: The Highlights BIO-Europe Spring is one of Europe’s biggest biotech partnering events with discussion topics ranging from platform technologies and manufacturing to biotech investments. Here are some of the key take-home reports from the proceedings. The event, which took place from March 20 to 22, in the budding biotech hub of Basel, Switzerland, was in full swing […] April 3, 2023 - 28 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Sofinnova Partners dives into digital medicine, funds new companies Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, has launched a new investment strategy focused on digital medicine. The strategy, which has already seen Sofinnova Partners investing in biotech companies, will be headed by partners Edward Kliphuis and Simon Turner. Sofinnova Digital Medicine will back entrepreneurs innovating at […] March 31, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Ablaze Pharmaceuticals to develop first-in-class therapy for liver cancer in China Ablaze Pharmaceuticals, a biotech company focused on developing targeted radiotherapy (TRT) to benefit cancer patients in China, is developing plans for a first-in-class novel peptide drug candidate against GPC3. The proprietary GPC3-targeting peptide is being licensed from RayzeBio. Upon in-license of product candidates by Ablaze from RayzeBio, Ablaze will be responsible for clinical development and […] March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Destiny Pharma gel reduces nasal staph in surgery patients Destiny Pharma has revealed data showing its drug reduced Staphylococcus aureus in the nasal passage of pre-op cardiac surgery patients. Destiny Pharma is a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections. The data was published in the journal Infection Control & Hospital Epidemiology. The paper was […] March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 Candidate found to inhibit malignant melanoma growth Malignant melanoma is a relatively aggressive type of skin cancer. When detected early, it is usually treatable by surgical resection only, but metastases develop, often spreading to distant areas. Currently, tumor thickness and the presence of ulceration are some of the known prognostic factors used as indicators of melanoma. Therefore, the discovery of markers to […] March 31, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Mar 2023 €260M fund addresses dementia investment shortfall EQT Life Sciences has closed its inaugural LSP Dementia Fund, raising approximately €260 million ($283 million) in fee-generating assets under management, meeting the hard cap and surpassing the target fund size of €100 million ($108.9 million). The LSP Dementia Fund is dedicated to investing in companies that are developing breakthrough drug therapies and medical technologies […] March 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 31 Mar 2023 How has the collapse of the Silicon Valley Bank affected the biotech industry? When investors got wind of Silicon Valley Bank (SVB) being forced to sell its treasury bonds at a loss, owing in part to surging interest rates in the past year – a move by the Federal Reserve to counteract rising inflation – panic followed a bank run. And in a swift spur of events, the […] March 31, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Podcast 31 Mar 2023Beyond Biotech podcast 40: Antibody-drug conjugates This episode of the podcast is an in-depth look at antibody drug conjugates (ADCs). Our guests are Dr Pini Tsukerman, chief scientific of Nectin Therapeutics, and Matthew Robinson, chief technology officer of Immunome. This episode of the podcast is sponsored by PHTA. Immunome Immunome’s Discovery Engine leverages the information stored in memory B cells to […] March 31, 2023 Share WhatsApp Twitter Linkedin Email
News and Trends 30 Mar 2023 Vaccitech announces positive topline data for chronic hepatitis study Vaccitech plc has announced positive topline final data from the HBV002 study, a phase 1b/2a clinical trial of VTP-300 in people with chronic hepatitis B (HBV) infection. Vaccitech is a clinical-stage biopharmaceutical company focused on the development of novel T cell immunotherapeutics to use the immune system to potentially treat and cure chronic infectious diseases, […] March 30, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email